MAPT (Ab-262) Antibody

What is MAPT (Ab-262) Antibody and what epitope does it recognize?

MAPT (Ab-262) Antibody is a rabbit polyclonal IgG antibody that recognizes the microtubule-associated protein Tau (MAPT). Specifically, this antibody targets a peptide sequence around amino acids 260-264 (I-G-S-T-E) derived from human Tau protein . This epitope is located outside the microtubule-binding repeat domains, in a region that plays a role in Tau's function as a linker protein. The antibody is reactive with human, mouse, and rat Tau protein, making it suitable for cross-species research applications .

How does MAPT (Ab-262) Antibody differ from phospho-specific Tau antibodies?

MAPT (Ab-262) Antibody is a total Tau antibody that recognizes Tau protein regardless of its phosphorylation state, whereas phospho-specific antibodies like Anti-Phospho-Tau (S262) target only Tau molecules phosphorylated at specific residues . The difference is significant because:

What experimental applications has MAPT (Ab-262) Antibody been validated for?

MAPT (Ab-262) Antibody has been validated for the following applications:

The antibody has demonstrated effective detection of Tau in mouse brain tissue extracts by Western blot . For research requiring immunohistochemistry (IHC) or immunofluorescence applications, additional validation would be necessary, as these are not listed among the recommended applications for this specific antibody.

What are the optimal conditions for using MAPT (Ab-262) Antibody in Western blot experiments?

For optimal Western blot results with MAPT (Ab-262) Antibody, the following protocol elements are recommended:

• Sample preparation: Proteins should be extracted using RIPA buffer containing 0.1% SDS, protease inhibitors, and phosphatase inhibitors

• Sample denaturation: Mix protein extracts 3:1 with 4× Laemmli buffer containing β-mercaptoethanol and heat at 95°C for 10 minutes

• Antibody dilution: Use at 1:500-1:1000 dilution for Western blot applications

• Storage conditions: Store the antibody at -20°C for long-term storage or at 4°C for up to one month if used frequently

• Avoid repeated freeze-thaw cycles to maintain antibody performance

These conditions should be optimized for specific experimental setups, particularly when detecting endogenous Tau at physiological levels, which can be challenging compared to overexpressed Tau .

How can I verify the specificity of MAPT (Ab-262) Antibody in my experimental system?

To verify antibody specificity, implement the following methodological approaches:

• Include appropriate controls:

  • Positive control: Recombinant Tau protein or lysates from cells overexpressing Tau

  • Negative control: Samples from MAPT knockout (MAPT−/−) animals or cells

  • Validation across concentrations: Test detection at both high (overexpressed) and low (endogenous) Tau levels

• Cross-reactivity assessment:

  • Test against recombinant MAP2 protein, which is structurally related to Tau and a common source of cross-reactivity

  • Compare signal patterns in wildtype versus MAPT knockout samples

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide sequence to demonstrate binding specificity

Recent comprehensive antibody validation studies have shown that over half of commercially available Tau antibodies exhibit non-selective binding to other proteins, emphasizing the importance of rigorous validation .

How does sample preparation affect MAPT (Ab-262) Antibody performance?

Sample preparation significantly impacts MAPT (Ab-262) Antibody performance:

• Buffer composition: Use RIPA buffer containing protease and phosphatase inhibitors to prevent protein degradation and preserve phosphorylation status

• Centrifugation: Spin lysates at 20,000 × g to remove genomic DNA and cellular debris that may interfere with antibody binding

• Storage considerations: Use low-protein-binding tubes and store samples at -80°C to maintain protein integrity

• Denaturation conditions: Complete denaturation with β-mercaptoethanol and heating is essential to expose the epitope for antibody recognition

For brain tissue samples specifically, quick freezing and mechanical homogenization in cold buffer are recommended to preserve protein integrity and epitope availability .

How does phosphorylation of Tau affect the binding of MAPT (Ab-262) Antibody?

While MAPT (Ab-262) Antibody targets a total Tau epitope rather than a phospho-specific site, phosphorylation status may still influence binding efficiency:

• Research has shown that phosphorylation can partially inhibit binding for many "total" Tau antibodies, affecting their ability to accurately quantify total Tau levels in highly phosphorylated samples

• The specific epitope recognized by MAPT (Ab-262) (amino acids 260-264) is in proximity to the Ser262 phosphorylation site, which is a known pathological phosphorylation site in Alzheimer's disease

• For comparative studies examining total Tau across samples with variable phosphorylation states, researchers should be aware of this potential confounding factor

When investigating heavily phosphorylated Tau samples, consider using multiple total Tau antibodies targeting different epitopes to ensure comprehensive detection.

Can MAPT (Ab-262) Antibody distinguish between different Tau isoforms?

MAPT (Ab-262) Antibody recognizes an epitope present in all six common Tau isoforms, as the targeted region (amino acids 260-264) is not within the alternatively spliced exons that differentiate Tau isoforms . Therefore:

• This antibody cannot directly distinguish between the six main isoforms (0N3R, 1N3R, 2N3R, 0N4R, 1N4R, and 2N4R)

• On Western blots, Tau isoforms appear as a series of closely spaced bands with apparent molecular weights ranging from 58 to 66 kDa, showing abnormal retardation in electrophoretic mobility compared to their predicted molecular weights (36.7 to 45.9 kDa)

• For isoform-specific detection, antibodies targeting regions encoded by alternatively spliced exons (like exon 10 for 4R specificity) would be required

When analyzing complex Tau expression patterns, consider using this antibody in conjunction with isoform-specific antibodies or a Tau ladder reference standard to identify specific isoforms .

What are the limitations of using MAPT (Ab-262) Antibody in detecting truncated Tau species?

The ability of MAPT (Ab-262) Antibody to detect truncated Tau species depends on whether the truncation affects the epitope region:

• The antibody targets amino acids 260-264 of human Tau, so truncations that remove this region will not be detected

• C-terminally truncated Tau species that retain the 260-264 region should be detectable

• N-terminally truncated species would be detected only if the truncation occurs before the 260-264 region

Recent research has identified C-terminally truncated versions of all main Tau isoforms in both control and tauopathy brain samples, highlighting the importance of epitope location when studying these species .

Why might I observe variable results with MAPT (Ab-262) Antibody in different experimental conditions?

Variable results with MAPT (Ab-262) Antibody may stem from several methodological factors:

• Sample preparation variations:

  • Incomplete protein denaturation leading to epitope masking

  • Degradation due to inadequate protease inhibition

  • Variable phosphorylation affecting epitope accessibility

• Technical considerations:

  • Blocking reagent composition influencing background signals

  • Antibody dilution optimization for specific sample types

  • Incubation time and temperature affecting binding kinetics

• Biological variables:

  • Expression levels of Tau varying across brain regions, cell types, or disease states

  • Presence of truncated Tau species lacking the target epitope

  • Competitive binding from other microtubule-associated proteins

To minimize variability, standardize protocols, include appropriate controls, and validate results with complementary techniques.

How can I distinguish between MAPT and MAP2 when using MAPT (Ab-262) Antibody?

Distinguishing between MAPT and MAP2 is crucial given their structural similarities and potential cross-reactivity:

• Molecular weight discrimination:

  • MAP2 isoforms (MAP2A/B ~280 kDa, MAP2C ~70 kDa, MAP2D ~75 kDa) generally have higher molecular weights than Tau isoforms (36.7-45.9 kDa, but migrate at 58-66 kDa on SDS-PAGE)

  • Use appropriate molecular weight markers and include recombinant standards

• Control experiments:

  • Test the antibody against recombinant MAP2 protein to assess potential cross-reactivity

  • Include MAPT knockout samples where only potential cross-reactive signals would remain

• Complementary approaches:

  • Perform parallel blots with validated MAP2-specific antibodies

  • Consider immunodepletion experiments to confirm specificity

Extensive validation studies have shown that several Tau antibodies cross-react with MAP2, emphasizing the importance of these controls .

What controls are essential when using MAPT (Ab-262) Antibody for studying Tau in neurodegenerative disease models?

When studying neurodegenerative disease models, the following controls are essential:

• Genetic controls:

  • MAPT knockout tissue/cells (MAPT−/−) to establish baseline and identify non-specific binding

  • Wild-type matched samples to determine physiological expression patterns

  • Humanized Tau (hTau) mouse models when studying human-specific epitopes or pathology

• Biochemical controls:

  • Recombinant Tau ladder showing all six isoforms for accurate band identification

  • Phosphorylated and non-phosphorylated recombinant Tau to assess phosphorylation effects on antibody binding

  • Dephosphorylated tissue samples (treated with phosphatases) to determine phosphorylation influence

• Disease-specific controls:

  • Age-matched control samples to account for age-related Tau modifications

  • Samples representing different stages of pathology to track disease progression

  • Positive control tissues with known Tau pathology (e.g., rTg4510 mouse model samples)

These controls help distinguish between physiological and pathological Tau species and ensure accurate interpretation of experimental results.

How can MAPT (Ab-262) Antibody be used to study Tau's role in neuronal polarity and function?

MAPT (Ab-262) Antibody can be strategically employed to investigate Tau's physiological roles:

• Studying Tau's dual binding functionality:

  • The antibody targets a region between Tau's N-terminus (which binds neural plasma membrane components) and C-terminus (which binds axonal microtubules)

  • This positioning makes it useful for studying Tau's function as a linker protein between these cellular components

• Neuronal polarity investigations:

  • Tau localization in the centrosome-defined domain of the neuronal cell body predetermines axonal polarity

  • Use the antibody in combination with centrosomal markers to study this relationship

• Cytoskeletal dynamics analysis:

  • Different Tau isoforms contribute differently to cytoskeletal plasticity versus stability

  • The antibody can help quantify total Tau levels when studying how short isoforms promote cytoskeletal plasticity and longer isoforms enhance stabilization

This fundamental research is essential for understanding how Tau dysfunction may contribute to neurodegenerative processes beyond simple aggregation mechanisms.

What methodological approaches can improve detection of low-abundance Tau species with MAPT (Ab-262) Antibody?

For detecting low-abundance Tau species, consider these methodological enhancements:

• Sample enrichment strategies:

  • Immunoprecipitation to concentrate Tau protein before Western blotting

  • Subcellular fractionation to isolate compartments with higher Tau concentrations

  • Sequential extraction protocols to separate soluble and insoluble Tau pools

• Signal amplification techniques:

  • Enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Biotin-streptavidin amplification systems

  • Tyramide signal amplification for immunohistochemical applications

• Optimized detection parameters:

  • Extended antibody incubation times at 4°C

  • Optimized blocking conditions to reduce background while maintaining sensitivity

  • Digital imaging systems with enhanced dynamic range

Recent extensive antibody validation studies have emphasized the importance of identifying antibodies capable of detecting even low, physiological levels of Tau expression with high selectivity .